Valeant to bid for Botox maker Allergan; Activist investor Ackman discloses $4.1B stake
NEW YORK, N.Y. – Valeant Pharmaceuticals has teamed up with activist investor Bill Ackman to make a bid for Botox maker Allergan.
Valeant said Monday that it intends to propose a merger with Allergan using a combination of Valeant stock and cash. The transaction size has not been disclosed, but Valeant expects the cash portion of the deal to be at least $15 billion.
In a separate filing, Ackman’s Pershing Square Capital Management said it owns a 9.7 per cent stake in Allergan worth $4.1 billion. Ackman’s stake would make a Allergan deal worth around $40 billion.
Allergan’s star product is Botox, the anti-wrinkle treatment. The company sold $2 billion in Botox last year, up roughly 12 per cent from the prior year.
Allergan’s stock jumped $28, or 20 per cent, to $170 in after-hours trading.
News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.
Join the Conversation!
Want to share your thoughts, add context, or connect with others in your community? Create a free account to comment on stories, ask questions, and join meaningful discussions on our new site.
Leave a Reply
You must be logged in to post a comment.